GRFS · Grifols SA
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
GRFS
this stock
Grifols SA
|
$5.32B | -16.4% | — | — | 0.5% |
|
LLY
ELI LILLY & Co
|
$1.14T | +9.4% | +44.7% | 40.7 | 0.7% |
|
JNJ
Johnson & Johnson
|
$658.24B | +28.4% | +6.0% | 31.7 | 0.9% |
|
ABBV
AbbVie Inc.
|
$464.58B | +13.0% | +8.6% | 74.3 | 1.0% |
|
MRK
Merck & Co., Inc.
|
$379.22B | +42.1% | +1.3% | 123.0 | 1.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| GRFS | -2.1% | -4.6% | -9.0% | -0.6% | -16.4% |
| SPY | +1.1% | +4.0% | +14.7% | +3.2% | +13.1% |
| vs SPY | -3.2% | -8.6% | -23.6% | -3.9% | -29.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.